Salvianolic acid A &amp; B: potential cytotoxic polyphenols in battle against cancer via targeting multiple signaling pathways

Tian, Qing; Rasul, Azhar; Sarfraz, Ayesha; Sarfraz, Iqra; Hussain, Ghulam; Anwar, Haseeb; Riaz, Ammara; Liu, Sitong; Wei, Wei; Jiang, Li; Li, Yongming

doi:10.7150/ijbs.37467

Cited by 47 publications

(28 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sal-B is a potential cytotoxic polyphenol against cancer via targeting multiple signaling pathways. Sal-B has been shown to trigger apoptosis through activation of caspases, reducing anti-apoptotic proteins (Bcl-2), activation of proapoptotic proteins (Bak, Bax), modulating PI3K/AKT/MAPK pathways, NF-κB inflammatory signaling inhibition, and ROS modulation [61]. Our data suggest that Sal-B may have a potential role to prevent the progression of breast cancer cells growth via its antioxidant, anti-angiogenic, and apoptotic effects.…”

Section: Discussionmentioning

confidence: 99%

Salvianolic Acid B Slows the Progression of Breast Cancer Cell Growth via Enhancement of Apoptosis and Reduction of Oxidative Stress, Inflammation, and Angiogenesis

Mohamed

Abdelsayed

Alhashim

et al. 2019

IJMS

View full text Add to dashboard Cite

Breast cancer is the current leading cause of cancer death in females worldwide. Although current chemotherapeutic drugs effectively reduce the progression of breast cancer, most of these drugs have many unwanted side effects. Salvianolic acid B (Sal-B) is a bioactive compound isolated from the root of Danshen Radix with potent antioxidant and anti-inflammatory properties. Since free radicals play a key role in the initiation and progression of tumor cells growth and enhance their metastatic potential, the current study was designed to investigate the antitumor activity of Sal-B and compare it with the antitumor activity of the traditional anticancer drug, cisplatin. In vitro, Sal-B decreased the human breast cancer adenocarcinoma (MCF-7) cells proliferation in a concentration and time dependent manner. In vivo and similar to cisplatin treatment, Sal-B significantly reduced tumor volume and increased the median survival when compared to tumor positive control mice group injected with Ehrlich solid carcinoma cell line (ESC). Sal-B decreased plasma level of malondialdehyde as a marker of oxidative stress and increased plasma level of reduced glutathione (GSH) as a marker of antioxidant defense when compared to control ESC injected mice. Either Sal-B or cisplatin treatment decreased tumor tissue levels of tumor necrosis factor (TNF-α), matrix metalloproteinase-8 (MMP-8), and Cyclin D1 in ESC treated mice. Contrary to cisplatin treatment, Sal-B did not decrease tumor tissue Ki-67 protein in ESC injected mice. Immunohistochemical analysis revealed that Sal-B or cisplatin treatment increased the expression of the apoptotic markers caspase-3 and P53. Although Sal-B or cisplatin significantly reduced the expression of the angiogenic factor vascular endothelial growth factor (VEGF) in ESC injected mice, only Sal-B reduced expression level of COX-2 in ESC injected mice. Our data suggest that Sal-B exhibits antitumor features against breast cancer cells possibly via enhancing apoptosis and reducing oxidative stress, inflammation, and angiogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Salvianolic Acid B Slows the Progression of Breast Cancer Cell Growth via Enhancement of Apoptosis and Reduction of Oxidative Stress, Inflammation, and Angiogenesis

Mohamed

Abdelsayed

Alhashim

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Salvianolic acid A (Sal‐A) is the key bioactive water‐soluble constituent of Salvia miltiorrhiza 15,16 . Studies have also verified that Sal‐A owned massive pharmacological function containing antioxidation, 17 antiplatelet aggregation 18 and against ischaemia/reperfusion injury 19 .…”

Section: Introductionmentioning

confidence: 99%

“…Sal‐A attenuates CCl4‐induced liver fibrosis via controlling many of signalling 16 . Sal‐A delays cancer development via prompting apoptosis, reducing cell cycle and preventing cancer metastasis 15 . Sal‐A reduces nasopharyngeal carcinoma cancer cell invasion ability by ERK/MMP‐2 expression 21 .…”

Section: Introductionmentioning

confidence: 99%

Salvianolic acid A blocks vasculogenic mimicry formation in human non‐small cell lung cancer via PI3K/Akt/mTOR signalling

Jin

Chen

Huang

et al. 2021

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Vasculogenic mimicry (VM) is associated with aggressive cancer cells. Salvianolic acid A (Sal‐A), an antioxidant and anti‐inflammatory agent, has bioactive properties from Salvia miltiorrhiza Bunge. Current investigation aspired to explore the activity of Sal‐A in the VM formation of non‐small cell lung cancer (NSCLC) and the mechanism underling this function. The CCK8, the scratch and boyden chemotaxis assay were presented to describe NSCLC cells viability, migration and invasion capabilities, respectively. The protein expression was verified by western blotting. In this report, Sal‐A caused a reduction in viability, metastasis and capillaries structure formation of NSCLC cells. Additionally, Sal‐A markedly prevented the key VM related proteins, containing EphA2, VE‐cadherin and MMP2. Besides, Sal‐A significantly diminished p‐PI3K, p‐Akt and p‐mTOR level in NSCLC cells. More importantly, SC79 pretreatment reversed Sal‐A inhibits NSCLC cells viability, metastasis and VM formation. These data exhibit that Sal‐A could block VM network formation in NSCLC cells through modulating the PI3K/Akt/mTOR signalling pathway.

show abstract

“…Neosperidin possess antidiabetic potential and used to improve and promote skin microcirculation [ 36 ]. Salvionic acid has been patented as antithrombotic agent and possesses other therapeutic value [ 37 , 38 ]. Ribostamycin sulfate is known to inhibit the protein synthesis in bacteria [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study

Singh

Kushwaha

Prajapati

et al. 2021

Computers in Biology and Medicine

View full text Add to dashboard Cite

Coronaviruses are known to infect respiratory tract and intestine. These viruses possess highly conserved viral macro domain A1pp having adenosine diphosphate (ADP)-ribose binding and phosphatase activity sites. A1pp inhibits adenosine diphosphate (ADP)-ribosylation in the host and promotes viral infection and pathogenesis. We performed in silico screening of FDA approved drugs and nucleoside analogue library against the recently reported crystal structure of SARS-CoV-2 A1pp domain. Docking scores and interaction profile analyses exhibited strong binding affinity of eleven FDA approved drugs and five nucleoside analogues NA 1 (−13.84), nadide (−13.65), citicholine (−13.54), NA 2 (−12.42), and NA 3 (−12.27). The lead compound NA 1 exhibited significant hydrogen bonding and hydrophobic interaction at the natural substrate binding site. The root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent accessible surface (SASA), hydrogen bond formation, principle component analysis, and free energy landscape calculations for NA 1 bound protein displayed stable complex formation in 100 ns molecular dynamics simulation, compared to unbound macro domain and natural substrate adenosine-5-diphosphoribose bound macro domain that served as a positive control. The molecular mechanics Poisson–Boltzmann surface area analysis of NA 1 demonstrated binding free energy of −175.978 ± 0.401 kJ/mol in comparison to natural substrate which had binding free energy of −133.403 ± 14.103 kJ/mol. In silico analysis by modelling tool ADMET and prediction of biological activity of these compounds further validated them as putative therapeutic molecules against SARS-CoV-2. Taken together, this study offers NA 1 as a lead SARS-CoV-2 A1pp domain inhibitor for future testing and development as therapeutics against human coronavirus.

show abstract

Salvianolic acid A & B: potential cytotoxic polyphenols in battle against cancer via targeting multiple signaling pathways

Cited by 47 publications

References 70 publications

Salvianolic Acid B Slows the Progression of Breast Cancer Cell Growth via Enhancement of Apoptosis and Reduction of Oxidative Stress, Inflammation, and Angiogenesis

Salvianolic Acid B Slows the Progression of Breast Cancer Cell Growth via Enhancement of Apoptosis and Reduction of Oxidative Stress, Inflammation, and Angiogenesis

Salvianolic acid A blocks vasculogenic mimicry formation in human non‐small cell lung cancer via PI3K/Akt/mTOR signalling

Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study

Contact Info

Product

Resources

About